A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01870739
First received: June 3, 2013
Last updated: April 15, 2014
Last verified: April 2014
  Purpose

This is the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. The results of this exploratory study will help to understand the mechanism of action of LCZ696 and used to inform the design of future clinical studies with LCZ696 in subjects with cardiovascular diseases.


Condition Intervention Phase
Hypertension
Drug: LCZ696
Drug: olmesartan
Other: placebo to LCZ696
Other: placebo to olmesartan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change from baseline in ascending aorta distensibility at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic distensibility.

  • Change from baseline in proximal descending aorta distensibility at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic distensibility.

  • Change from baseline in distal descending aorta distensibility at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic distensibility.


Secondary Outcome Measures:
  • Change from baseline in local aortic strain at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic strain.

  • Change from baseline in regional aortic pulse wave velocity at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of regional aortic pulse wave velocity.

  • Change from baseline in Central blood pressure at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in augmentation pressure at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Augmentation pressure is the added pressure during systole due to wave reflection.

  • Change from baseline in augmentation index at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Augmentation index is the percentage of the central pulse pressure due to wave reflection.

  • Change from baseline in pulse wave velocity at 12 weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
  • Number of patients with reported adverse events, serious adverse events and death [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 140
Study Start Date: October 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LCZ696
Patients will receiveLCZ696 once daily (q.d.) + placebo to olmesartan q.d.
Drug: LCZ696 Other: placebo to olmesartan
placebo
Active Comparator: olmesartan
Patients will receive olmesartan once daily (q.d.) + mg placebo to LCZ696 q.d.
Drug: olmesartan Other: placebo to LCZ696
placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Subjects with essential hypertension, untreated or currently taking antihypertensive therapy

Key exclusion Criteria:

  • women of child bearing potential (WOCBP) if not on highly effective contraception
  • Malignant or severe hypertension (grade 3 of WHO classification)
  • History or evidence of a secondary form of hypertension
  • Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.
  • Previous or current diagnosis of heart failure (New York Heart Association Class II-IV).

Other protocol defined inclusion and exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01870739

Contacts
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals

Locations
Germany
Novartis Investigative Site Not yet recruiting
Berlin, Germany, 13125
Novartis Investigative Site Recruiting
Berlin, Germany, 10117
Novartis Investigative Site Recruiting
Erlangen, Germany, 91054
Novartis Investigative Site Not yet recruiting
Luebeck, Germany, 23562
Switzerland
Novartis Investigative Site Not yet recruiting
Basel, Switzerland, 4031
United Kingdom
Novartis Investigative Site Not yet recruiting
Glasgow, Scotland, United Kingdom, G12 8TA
Novartis Investigative Site Not yet recruiting
London, United Kingdom, EC1A 7BE
Novartis Investigative Site Not yet recruiting
London, United Kingdom, SW 6NP
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01870739     History of Changes
Other Study ID Numbers: CLCZ696A2224, 2012-005720-15
Study First Received: June 3, 2013
Last Updated: April 15, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
LCZ696,
Hypertension,
Aortic stiffness,
Central blood pressure,
Cardiovascular MRI

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Olmesartan
Olmesartan medoxomil
3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 26, 2014